Europe (WHO region) vs Puerto Rico: Previously treated cases tested for RR-/MDR-TB
Europe (WHO region)
90.0%
in 2024
Puerto Rico
100.0%
in 2023
Europe (WHO region) rank
2nd
Puerto Rico rank
1st
Previously treated cases tested for RR-/MDR-TB over time
- Europe (WHO region)
- Puerto Rico
How they compare
Puerto Rico currently reports 100.0% against 90.0% in Europe (WHO region), a difference of 10.0%.
That makes Puerto Rico's figure about 1.1 times Europe (WHO region)'s.
The two have swapped places 2 times across 8 shared years of data; in 2010 it was Puerto Rico ahead.
Europe (WHO region) ranks 2nd and Puerto Rico ranks 1st of 11 groups.
Puerto Rico has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe (WHO region) | Puerto Rico | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 59.3% | 87.5% | 28.2% | Puerto Rico |
| 2020s | 95.5% | 100.0% | 4.5% | Puerto Rico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Europe (WHO region) or Puerto Rico?
- Puerto Rico, at 100.0% against 90.0% in Europe (WHO region) as of 2023.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Europe (WHO region) and Puerto Rico?
- 10.0%, with Puerto Rico ahead.
- How many years of comparable data are there for Europe (WHO region) and Puerto Rico?
- 8 years are reported by both, from 2010 to 2023.
- How do Europe (WHO region) and Puerto Rico rank globally for previously treated cases tested for rr-/mdr-tb?
- Europe (WHO region) ranks 2nd and Puerto Rico ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.